PHARMACEUTICAL COMPOSITION COMPRISING SETMAR INHIBITOR FOR PREVENTING OR TREATING CANCER

• Main Authors: GONG, Jeong Ryeol, KIM, Ju Hee, CHO, Kwang Hyun
• Format: Patent
• Language: English; French; Korean
• Published: 14.09.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

The present invention relates to a composition comprising a SETMAR inhibitor for preventing or treating cancer. It has been identified that if SETMAR is inhibited in cancer cells, carcinogenesis reversion, which is the differentiation of cancer cells into normal cells, is successfully achieved, and thus, unlike conventional anticancer agents that simply induce cancer cell death, the present invention can be effectively used as a treatment method excluding the side effect of normal cell death that can occur during anticancer treatment, and converting cancer cells into normal cells. La présente invention concerne une composition comprenant un inhibiteur de SETMAR pour la prévention ou le traitement du cancer. Il a été identifié que si SETMAR est inhibé dans les cellules cancéreuses, cela permet la réversion de la carcinogenèse, c'est-à-dire la différenciation des cellules cancéreuses en cellules normales. Ainsi, contrairement aux agents anticancéreux conventionnels qui induisent simplement la mort des cellules cancéreuses, la présente invention peut être utilisée efficacement comme méthode de traitement excluant l'effet secondaire de la mort des cellules normales qui peut survenir lors d'un traitement anticancéreux, et convertissant les cellules cancéreuses en cellules normales. 본 발명은 SETMAR 억제제를 포함하는 암 예방 또는 치료용 조성물에 관한 것으로, 암세포에서 SETMAR을 억제하는 경우, 암세포의 정상 세포로의 분화인, 암화 과정의 가역화가 성공적으로 달성됨을 규명한 바, 본 발명은 단순히 암세포의 사멸을 유도하는 종래 항암제와 달리, 항암 치료시 발생할 수 있는 정상 세포가 사멸되는 부작용을 배제하고, 암세포를 정상 세포로 전환시키는 치료 방법으로서 유용하게 활용할 수 있다.